Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Q2 2021 vs. Q1 2021
How the institutions holding Finch Therapeutics Group, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 36 | 46 | +10 |
| Shares | 6.81M | 5.51M | −1.30M (−19.1%) |
| Value | $108.9M | $77.2M | −$31.6M (−29.1%) |
New holders (25)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (15)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| HealthCor Management, L.P. | 150,000 | $2.42M |
| Sphera Funds Management Ltd. | 150,000 | $2.39M |
| Blackstone Group Inc. | 125,000 | $2.02M |
| Monashee Investment Management LLC | 125,000 | $2.02M |
| Goldman Sachs Group Inc | 59,124 | $955.0K |
| Marshall Wace North America L.P. | 47,350 | $753.0K |
| Alyeska Investment Group, L.P. | 39,700 | $641.0K |
| Squarepoint Ops LLC | 30,000 | $485.0K |
| Caas Capital Management LP | 20,000 | $323.0K |
| Norges Bank | 20,000 | $318.0K |
| Wellington Management Group LLP | 18,431 | $293.0K |
| Tudor Investment Corp Et Al | 17,259 | $279.0K |
| Point72 Hong Kong Ltd | 14,827 | $239.0K |
| Maven Securities LTD | 11,837 | $185.0K |
| Point72 Asset Management, L.P. | 1,433 | $23.0K |